Generic molecule: omacetaxine mepesuccinate
Company: Teva Pharmaceutical Industries
Approval date: Oct. 26
The scoop: Teva ($TEVA) got the FDA's OK for Synribo to treat chronic myelogenous leukemia (CML) patients whose cancer has remained after taking two or more previous tyrosine kinase inhibitors (TKIs). Synribo became the second drug the agency approved to treat this form of leukemia in as many months, after the FDA's nod for Pfizer's Bosulif in September.